Imipenem/cilastatin sodium (IPM/CS) as an embolic agent for transcatheter arterial embolisation: a preliminary clinical study of gastrointestinal bleeding from neoplasms

SpringerPlus

Table 1 Summary of clinical course

Pt. no	Age	Sex	Disease	Outcome	Proc no.	Extravasation	Embolized artery	IPM/CS (g)	Rebleeding (day)
1	53	M	Pancreatic cancer	Died at day 247	1	+	PA	0.5	-
2	59	M	Malignat lymphoma	Died at day 163	2	+	JA	2.2	0
			Malignat lymphoma	Died at day 163	3		JA	0.6	-
3	68	M	Pancreatic lymphoma	Died at day 48	4		IA	0.5	21
			Pancreatic lymphoma	Died at day 48	5		IA	1.0	1
4	73	M	Pancreatic cancer	Transferred at day 44	6		PA	1.5	10
			Pancreatic cancer	Transferred at day 44	7		PA	1.4	-
5	64	M	Metastasis to the pancreas	Died at day 224	8		PA	0.9	-
6	46	F	Invasion of cervical cancer to the rectum	Transferred at day 339	9 10		IRA	0.4	0
							SRA	0.4	-
7	43	F	Colon cancer	Died at day 37	11	+	LCA		-

Pt. no., patient number; Proc. no., procedure number; PA, pancreatic arcade; JA, jejunal artery; IA, ileal artery; RCC, renal cell carcinoma; IRA, inferior rectum artery; SRA, superior rectum artery; LCA; left colic artery.